Veradermics (MANE) Cash from Financing Activities (2025 - 2026)

Veradermics (MANE) reported Cash from Financing Activities of $269.1 million for Q1 2026, up 3094.98% on a YoY basis from $8.4 million in Q1 2025, and up 3094.98% quarter-over-quarter from $8.4 million in Q1 2025.

Veradermics (MANE) Cash from Financing Activities (2025 - 2026) Analysis & Trends

Veradermics has reported Cash from Financing Activities for 2 years, with the latest figure at $269.1 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 7.00 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -600,000.00
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 53,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -538.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - 85,464.43
10 Veradermics 2.13 Bn 2.13 Bn - 269.11 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 269.11 Mn
Mar 31, 2026 269.11 Mn
Mar 31, 2025 8.42 Mn
Mar 31, 2025 8.42 Mn